These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 19585395)
1. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Berwaerts J; Cleton A; Herben V; van de Vliet I; Chang I; van Hoek P; Eerdekens M Pharmacopsychiatry; 2009 Jul; 42(4):158-63. PubMed ID: 19585395 [TBL] [Abstract][Full Text] [Related]
2. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Fowler JA; Bettinger TL; Argo TR Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262 [TBL] [Abstract][Full Text] [Related]
3. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Thyssen A; Cleton A; Talluri K; Leempoels J; Janssens L; Boom S; Eerdekens M Hum Psychopharmacol; 2009 Oct; 24(7):532-9. PubMed ID: 19693799 [TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. Si T; Shu L; Liu Y; Su YA; Guo C; Zhang H Hum Psychopharmacol; 2010 Jul; 25(5):404-9. PubMed ID: 20589922 [TBL] [Abstract][Full Text] [Related]
5. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908 [TBL] [Abstract][Full Text] [Related]
6. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. Boom S; Talluri K; Janssens L; Remmerie B; De Meulder M; Rossenu S; van Osselaer N; Eerdekens M; Cleton A J Clin Pharmacol; 2009 Nov; 49(11):1318-30. PubMed ID: 19713555 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460 [TBL] [Abstract][Full Text] [Related]
9. Paliperidone extended-release for the treatment of schizophrenia. Marino J; Caballero J Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223 [TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Luthringer R; Staner L; Noel N; Muzet M; Gassmann-Mayer C; Talluri K; Cleton A; Eerdekens M; Battisti WP; Palumbo JM Int Clin Psychopharmacol; 2007 Sep; 22(5):299-308. PubMed ID: 17690599 [TBL] [Abstract][Full Text] [Related]
11. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482 [TBL] [Abstract][Full Text] [Related]
12. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706 [TBL] [Abstract][Full Text] [Related]
13. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials. Janicak PG; Wu JH; Mao L Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166 [TBL] [Abstract][Full Text] [Related]
14. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. Berwaerts J; Lane R; Nuamah IF; Lim P; Remmerie B; Hough DW J Affect Disord; 2011 Mar; 129(1-3):252-60. PubMed ID: 20947174 [TBL] [Abstract][Full Text] [Related]
15. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Pani L; Marchese G Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589 [TBL] [Abstract][Full Text] [Related]
16. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. Canuso CM; Lindenmayer JP; Kosik-Gonzalez C; Turkoz I; Carothers J; Bossie CA; Schooler NR J Clin Psychiatry; 2010 May; 71(5):587-98. PubMed ID: 20492853 [TBL] [Abstract][Full Text] [Related]
19. [Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale]. Rusconi AC; Carlone C; Muscillo M; Piccione M Riv Psichiatr; 2009; 44(4):267-72. PubMed ID: 20066799 [TBL] [Abstract][Full Text] [Related]